Shopping Cart

Your shopping cart is currently empty

Mitiperstat

Name: Mitiperstat
Brand: TargetMol
SKU: T61028
Price: 158 USD
Availability: InStock
Rating: 5 (10 reviews)

(Synonyms: AZD4831) Copy Product Info

🥰Excellent

Synonyms: AZD4831

Catalog No. T61028 Copy Product Info

Purity: 98.36%

🥰Excellent

Mitiperstat (AZD-4831) is an irreversible, highly selective, oral myeloperoxidase (MPO) inhibitor. Mitiperstat inhibits MPO and thyroid peroxidase (TPO) with IC₅₀ values of 1.5 nM and 0.69 μM, respectively. Mitiperstat exhibits weak inhibition of CYP3A4 with an IC₅₀ of 6 μM. Mitiperstat is suitable for research into diseases such as chronic obstructive pulmonary disease, heart failure with preserved ejection fraction, and non-alcoholic steatohepatitis.

Cas No. 1933460-19-5

Customer service consultation

Pack Size	Price	USA Stock	Global Stock
1 mg	$158	In Stock	In Stock
5 mg	$396	In Stock	In Stock
10 mg	$479	In Stock	In Stock
25 mg	$778	In Stock	In Stock
50 mg	$987	-	In Stock
100 mg	$1,380	-	In Stock
1 mL x 10 mM (in DMSO)	$436	In Stock	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:98.36%

Appearance:Solid

Color:Yellow

Resource Download

COA HNMR HPLC

Product Introduction

Bioactivity

Description	Mitiperstat (AZD-4831) is an irreversible, highly selective, oral myeloperoxidase (MPO) inhibitor. Mitiperstat inhibits MPO and thyroid peroxidase (TPO) with IC₅₀ values of 1.5 nM and 0.69 μM, respectively. Mitiperstat exhibits weak inhibition of CYP3A4 with an IC₅₀ of 6 μM. Mitiperstat is suitable for research into diseases such as chronic obstructive pulmonary disease, heart failure with preserved ejection fraction, and non-alcoholic steatohepatitis.
In vivo	Methods: BALB/c mice were intraperitoneally injected with yeast polysaccharides to induce neutrophilic peritonitis. Mitiperstat (0.01, 0.1, 1.0, 10 μmol/kg) was administered orally 2 hours prior to modeling. Mice were euthanized 2 hours after yeast polysaccharide injection. Results: Mitiperstat exhibited dose-dependent inhibition of peritoneal MPO activity. The lowest effective dose was 0.1 μmol/kg (total plasma concentration 1.7 nM at 4 hours post-administration). [1] Methods: Beagle dogs and SD rats received Mitiperstat at 100 mg/kg/day (9 months) and 125 mg/kg/day (6 months), respectively. Body weight, food intake, and pathology were monitored to determine the No Observed Adverse Effect Level (NOAEL). Results: No abnormalities in body weight, food intake, or pathology were observed in Beagle dogs or SD rats at the maximum dose. [1]
Synonyms	AZD4831

Chemical Properties

Molecular Weight	334.82
Formula	C₁₅H₁₅ClN₄OS
Cas No.	1933460-19-5
Smiles	C(N1C2=C(C(=O)NC1=S)NC=C2)C3=C([C@@H](C)N)C=C(Cl)C=C3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 135 mg/mL (403.2 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.99 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.9867 mL	14.9334 mL	29.8668 mL	149.3340 mL
5 mM	0.5973 mL	2.9867 mL	5.9734 mL	29.8668 mL
10 mM	0.2987 mL	1.4933 mL	2.9867 mL	14.9334 mL
20 mM	0.1493 mL	0.7467 mL	1.4933 mL	7.4667 mL
50 mM	0.0597 mL	0.2987 mL	0.5973 mL	2.9867 mL
100 mM	0.0299 mL	0.1493 mL	0.2987 mL	1.4933 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.